Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children
Highlights • CMV shedding is common in Mali, a malaria-endemic area. • Most children have low level of CMV shedding in the urine. • Artemisinin-based therapy for malaria may decrease CMV shedding in urine.
Saved in:
Published in | Journal of clinical virology Vol. 77; pp. 40 - 45 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.04.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Highlights • CMV shedding is common in Mali, a malaria-endemic area. • Most children have low level of CMV shedding in the urine. • Artemisinin-based therapy for malaria may decrease CMV shedding in urine. |
---|---|
AbstractList | Background Artemisinins, commonly used to treat malaria, have shown activity against cytomegalovirus (CMV) in vitro, in an animal model, and in case reports; however, the in vivo anti-CMV activity has not been well investigated. Objectives To evaluate whether artemisinins affect CMV shedding among subjects co-infected with CMV and malaria. Study design A prospective observational study of children in Mali (6 month-10 year) presenting with fever. Urine samples were collected at day 0, 3, and 14 from children treated with artemether-lumefantrine (Coartem registered ) for malaria and those who had other illnesses not treated with Coartem. CMV DNA was quantified using a real-time PCR. Resulting urine viral loads were compared between the groups at three time points. Results 164 malaria cases and 143 non-malaria comparisons were enrolled. Eighty-one (49%) cases and 88 (62%) comparisons shed CMV at day 0. Day 0 and day 3 viral loads were similar, but at day 14 the median viral load of cases was lower than that of comparisons (360 vs 720 copies/mL or 2.56 vs 2.86 log10), p =0.059. A stratified analysis of day 0 high viral shedders (defined as >1000 copies/mL) showed significantly lower median viral load at day 14 among cases (490 copies/mL, 2.69 log10) vs comparisons (1200 copies/mL, 3.08 log10), p =0.045. Conclusion A high rate of urinary CMV shedding was found in a malaria-endemic area. Among high virus shedders artemether-lumefantrine decreased urine viral load, but the effect was not observed when analysis of both high and low shedders was performed. These results support additional studies of artemisinin dosing and duration in CMV infection. Artemisinins, commonly used to treat malaria, have shown activity against cytomegalovirus (CMV) in vitro, in an animal model, and in case reports; however, the in vivo anti-CMV activity has not been well investigated. To evaluate whether artemisinins affect CMV shedding among subjects co-infected with CMV and malaria. A prospective observational study of children in Mali (6 month-10 year) presenting with fever. Urine samples were collected at day 0, 3, and 14 from children treated with artemether-lumefantrine (Coartem(®)) for malaria and those who had other illnesses not treated with Coartem. CMV DNA was quantified using a real-time PCR. Resulting urine viral loads were compared between the groups at three time points. 164 malaria cases and 143 non-malaria comparisons were enrolled. Eighty-one (49%) cases and 88 (62%) comparisons shed CMV at day 0. Day 0 and day 3 viral loads were similar, but at day 14 the median viral load of cases was lower than that of comparisons (360 vs 720 copies/mL or 2.56 vs 2.86 log10), p=0.059. A stratified analysis of day 0 high viral shedders (defined as >1000 copies/mL) showed significantly lower median viral load at day 14 among cases (490 copies/mL, 2.69 log10) vs comparisons (1200 copies/mL, 3.08 log10), p=0.045. A high rate of urinary CMV shedding was found in a malaria-endemic area. Among high virus shedders artemether-lumefantrine decreased urine viral load, but the effect was not observed when analysis of both high and low shedders was performed. These results support additional studies of artemisinin dosing and duration in CMV infection. Highlights • CMV shedding is common in Mali, a malaria-endemic area. • Most children have low level of CMV shedding in the urine. • Artemisinin-based therapy for malaria may decrease CMV shedding in urine. •CMV shedding is common in Mali, a malaria-endemic area.•Most children have low level of CMV shedding in the urine.•Artemisinin-based therapy for malaria may decrease CMV shedding in urine. Artemisinins, commonly used to treat malaria, have shown activity against cytomegalovirus (CMV) in vitro, in an animal model, and in case reports; however, the in vivo anti-CMV activity has not been well investigated. To evaluate whether artemisinins affect CMV shedding among subjects co-infected with CMV and malaria. A prospective observational study of children in Mali (6 month–10 year) presenting with fever. Urine samples were collected at day 0, 3, and 14 from children treated with artemether-lumefantrine (Coartem®) for malaria and those who had other illnesses not treated with Coartem. CMV DNA was quantified using a real-time PCR. Resulting urine viral loads were compared between the groups at three time points. 164 malaria cases and 143 non-malaria comparisons were enrolled. Eighty-one (49%) cases and 88 (62%) comparisons shed CMV at day 0. Day 0 and day 3 viral loads were similar, but at day 14 the median viral load of cases was lower than that of comparisons (360 vs 720 copies/mL or 2.56 vs 2.86 log10), p=0.059. A stratified analysis of day 0 high viral shedders (defined as >1000 copies/mL) showed significantly lower median viral load at day 14 among cases (490 copies/mL, 2.69 log10) vs comparisons (1200 copies/mL, 3.08 log10), p=0.045. A high rate of urinary CMV shedding was found in a malaria-endemic area. Among high virus shedders artemether-lumefantrine decreased urine viral load, but the effect was not observed when analysis of both high and low shedders was performed. These results support additional studies of artemisinin dosing and duration in CMV infection. BACKGROUNDArtemisinins, commonly used to treat malaria, have shown activity against cytomegalovirus (CMV) in vitro, in an animal model, and in case reports; however, the in vivo anti-CMV activity has not been well investigated.OBJECTIVESTo evaluate whether artemisinins affect CMV shedding among subjects co-infected with CMV and malaria.STUDY DESIGNA prospective observational study of children in Mali (6 month-10 year) presenting with fever. Urine samples were collected at day 0, 3, and 14 from children treated with artemether-lumefantrine (Coartem(®)) for malaria and those who had other illnesses not treated with Coartem. CMV DNA was quantified using a real-time PCR. Resulting urine viral loads were compared between the groups at three time points.RESULTS164 malaria cases and 143 non-malaria comparisons were enrolled. Eighty-one (49%) cases and 88 (62%) comparisons shed CMV at day 0. Day 0 and day 3 viral loads were similar, but at day 14 the median viral load of cases was lower than that of comparisons (360 vs 720 copies/mL or 2.56 vs 2.86 log10), p=0.059. A stratified analysis of day 0 high viral shedders (defined as >1000 copies/mL) showed significantly lower median viral load at day 14 among cases (490 copies/mL, 2.69 log10) vs comparisons (1200 copies/mL, 3.08 log10), p=0.045.CONCLUSIONA high rate of urinary CMV shedding was found in a malaria-endemic area. Among high virus shedders artemether-lumefantrine decreased urine viral load, but the effect was not observed when analysis of both high and low shedders was performed. These results support additional studies of artemisinin dosing and duration in CMV infection. |
Author | Forman, Michael Haidara, Aboubecrin Sedhigh A Maiga, Hamma Vaidya, Dhananjay Djimde, Abdoulaye Sangare, Cheik Oumar Arav-Boger, Ravit Barger-Kamate, Breanna |
AuthorAffiliation | 5 Johns Hopkins University, Department of Pediatrics, Division of Pediatric Infectious Disease, Baltimore, Maryland, USA 1 Johns Hopkins University, Department of Pediatrics, Division of Pediatric Emergency Medicine, Baltimore, Maryland, USA 2 Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, Maryland, USA 3 Malaria Research and Training Center, Bamako, Mali 4 Johns Hopkins University, Department of Medicine, Baltimore, Maryland, USA |
AuthorAffiliation_xml | – name: 3 Malaria Research and Training Center, Bamako, Mali – name: 1 Johns Hopkins University, Department of Pediatrics, Division of Pediatric Emergency Medicine, Baltimore, Maryland, USA – name: 2 Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, Maryland, USA – name: 5 Johns Hopkins University, Department of Pediatrics, Division of Pediatric Infectious Disease, Baltimore, Maryland, USA – name: 4 Johns Hopkins University, Department of Medicine, Baltimore, Maryland, USA |
Author_xml | – sequence: 1 fullname: Barger-Kamate, Breanna – sequence: 2 fullname: Forman, Michael – sequence: 3 fullname: Sangare, Cheik Oumar – sequence: 4 fullname: Haidara, Aboubecrin Sedhigh A – sequence: 5 fullname: Maiga, Hamma – sequence: 6 fullname: Vaidya, Dhananjay – sequence: 7 fullname: Djimde, Abdoulaye – sequence: 8 fullname: Arav-Boger, Ravit |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26895228$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUsuO1DAQjNAi9gEfwAX5uBwSHDt-REgrodHykFbiAJwtj92Z8eDYi50Mmh_gu3F2lhVwQJzc7q4qlV19Xp2EGKCqnre4aXHLX-2andk3pJQNJg3G_FF11kpBa9ZzcVJqKnnNGSWn1XnOO4xbRjvxpDolXPaMEHlW_bgeBjATigPSaYIRpi2k2s8jDDpMyQVAl6t4N3qJYkDmMMURNtrHvUtzRvMdpNTaIx-1RXbpbJAOFg3R-_h9uU0J9DRCmEovoVF7nZxGrshtnbcJwtPq8aB9hmf350X15e3159X7-ubjuw-rNze1YbSfajkYInuqLYGerAnBjA1SMiHlek0Hyy3mTDJtRK_xQIFx2zHGu66jmEmJLb2oro66t_N6BGuKpeJc3SY36nRQUTv15yS4rdrEvepETwTpisDlvUCK32bIkxpdNuC9DhDnrFohGek6LPl_QAXtiOx6UaDtEWpSzDnB8OCoxWqJWu1UiVotUStMVIm6cF78_pQHxq9sC-D1EQDlQ_cOksrGQTBgXSqRKxvdP-Wv_mIb74Iz2n-FA-RdnFMoSalW5UJQn5ZdW1at5bjQBac_AXT-0vg |
CitedBy_id | crossref_primary_10_1007_s40203_021_00093_y crossref_primary_10_2217_fvl_2016_0125 crossref_primary_10_1016_j_antiviral_2018_02_013 crossref_primary_10_1007_s40801_020_00182_y crossref_primary_10_1007_s12042_019_09228_0 crossref_primary_10_1002_phar_1987 crossref_primary_10_1099_jgv_0_001795 crossref_primary_10_1093_infdis_jix188 crossref_primary_10_1158_1078_0432_CCR_16_1490 crossref_primary_10_3390_microorganisms8010085 crossref_primary_10_1002_gch2_202300030 crossref_primary_10_1021_acs_jcim_1c00683 crossref_primary_10_3390_ijms21155578 crossref_primary_10_1016_j_biotechadv_2018_01_001 crossref_primary_10_1016_j_medmal_2018_01_004 |
Cites_doi | 10.1128/AAC.00893-13 10.1097/QCO.0b013e32834cfb58 10.1001/jama.2010.423 10.1086/591195 10.1056/NEJMoa1404599 10.1016/S0140-6736(03)15162-8 10.1182/blood.V97.4.867 10.1371/journal.pone.0010370 10.1084/jem.190.2.177 10.1016/j.antiviral.2013.10.014 10.1086/587106 10.1128/AAC.00519-12 10.1007/s40506-014-0021-5 10.1002/rmv.1814 10.1002/(SICI)1096-9071(200004)60:4<455::AID-JMV14>3.0.CO;2-Q 10.1111/1469-0691.12594 10.1186/1743-422X-8-40 10.1016/j.jcv.2013.06.008 10.1016/j.jcv.2010.06.018 10.2217/fvl.12.8 10.1007/s00109-001-0300-8 10.1016/j.bmc.2013.04.027 |
ContentType | Journal Article |
Copyright | Elsevier B.V. 2016 Elsevier B.V. Copyright © 2016 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: Elsevier B.V. – notice: 2016 Elsevier B.V. – notice: Copyright © 2016 Elsevier B.V. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7U9 C1K F1W H94 H95 H97 L.G M7N 5PM |
DOI | 10.1016/j.jcv.2016.02.006 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Virology and AIDS Abstracts Environmental Sciences and Pollution Management ASFA: Aquatic Sciences and Fisheries Abstracts AIDS and Cancer Research Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Aquatic Science & Fisheries Abstracts (ASFA) Professional Algology Mycology and Protozoology Abstracts (Microbiology C) PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Aquatic Science & Fisheries Abstracts (ASFA) Professional Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) ASFA: Aquatic Sciences and Fisheries Abstracts AIDS and Cancer Research Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Environmental Sciences and Pollution Management |
DatabaseTitleList | Aquatic Science & Fisheries Abstracts (ASFA) Professional MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1873-5967 |
EndPage | 45 |
ExternalDocumentID | 10_1016_j_jcv_2016_02_006 26895228 S1386653216000676 1_s2_0_S1386653216000676 |
Genre | Research Support, American Recovery and Reinvestment Act Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | Mali |
GeographicLocations_xml | – name: Mali |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: 1R01AI093701 – fundername: NIAID NIH HHS grantid: T32 AI052071 – fundername: NIAID NIH HHS grantid: R01 AI093701 – fundername: NICHD NIH HHS grantid: U54 HD079123 – fundername: NIDCD NIH HHS grantid: R01 DC013550 – fundername: FIC NIH HHS grantid: R24 TW007988 |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 4.4 457 4CK 4G. 53G 5GY 5VS 7-5 71M 8P~ AAAJQ AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXKI AAXUO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADVLN AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CJTIS CS3 D-I DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HX~ HZ~ IHE J1W KOM LUGTX M41 MO0 N9A O-L O9- OAUVE OD- OO. OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSI SSZ T5K UNMZH Z5R ~G- AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7U9 C1K F1W H94 H95 H97 L.G M7N 5PM |
ID | FETCH-LOGICAL-c539t-8fc2893ad2e92b22055f885788bb3fd6d06585ac79a0f3e56d4556444305880d3 |
IEDL.DBID | .~1 |
ISSN | 1386-6532 |
IngestDate | Tue Sep 17 21:08:15 EDT 2024 Fri Oct 25 10:36:03 EDT 2024 Fri Oct 25 21:40:58 EDT 2024 Thu Sep 26 17:48:07 EDT 2024 Sat Sep 28 07:57:42 EDT 2024 Fri Feb 23 02:34:14 EST 2024 Tue Oct 15 22:57:34 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Cytomegalovirus Malaria Urine viral load Artemether-lumefantrine |
Language | English |
License | Copyright © 2016 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c539t-8fc2893ad2e92b22055f885788bb3fd6d06585ac79a0f3e56d4556444305880d3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 Breanna Barger-Kamate and Michael Forman are co-primary authors |
ORCID | 0000-0002-5363-167X |
OpenAccessLink | https://europepmc.org/articles/pmc4792724?pdf=render |
PMID | 26895228 |
PQID | 1773428497 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4792724 proquest_miscellaneous_1785244086 proquest_miscellaneous_1773428497 crossref_primary_10_1016_j_jcv_2016_02_006 pubmed_primary_26895228 elsevier_sciencedirect_doi_10_1016_j_jcv_2016_02_006 elsevier_clinicalkeyesjournals_1_s2_0_S1386653216000676 |
PublicationCentury | 2000 |
PublicationDate | 2016-04-01 |
PublicationDateYYYYMMDD | 2016-04-01 |
PublicationDate_xml | – month: 04 year: 2016 text: 2016-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Journal of clinical virology |
PublicationTitleAlternate | J Clin Virol |
PublicationYear | 2016 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Germi, Mariette, Alain, Lupo, Thiebaut, Brion, Epaulard, Saint Raymond, Malvezzi, Morand (bib0080) 2014; 101 La Rosa, Diamond (bib0125) 2012; 7 Adjuik, Babiker, Garner, Olliaro, Taylor, White, International Artemisinin Study (bib0035) 2004; 363 Efferth, Romero, Wolf, Stamminger, Marin, Marschall (bib0045) 2008; 47 Lumbreras, Manual, Len, ten Berge, Sgarabotto, Hirsch (bib0005) 2014; 20 He, Park, Cai, Kapoor, Forman, Mott, Posner, Arav-Boger (bib0060) 2012; 56 Nichols, Corey, Gooley, Drew, Miner, Huang, Davis, Boeckh (bib0120) 2001; 97 Boppana, Ross, Novak, Shimamura, Tolan, Palmer, Ahmed, Michaels, Sanchez, Bernstein, Britt, Fowler, National Institute on Deafness and Other Communication Disorders CMV and Hearing Multicenter Screening Study (bib0130) 2010; 303 Gantt, Huang, Magaret, Bunts, Selke, Wald, Rosenthal, Dorsey, Casper (bib0085) 2013; 58 He, Forman, Mott, Venkatadri, Posner, Arav-Boger (bib0095) 2013; 57 Buyck, Griffiths, Emery (bib0115) 2010; 49 Hamilton, van Zuylen, Shand, Scott, Naing, Hall, Craig, Rawlinson (bib0010) 2014; 24 Emery, Cope, Bowen, Gor, Griffiths (bib0135) 1999; 190 Naing, Scott, Shand, Hamilton, van Zuylen, Basha, Hall, Craig, Rawlinson (bib0015) 2015 Efferth, Marschall, Wang, Huong, Hauber, Olbrich, Kronschnabl, Stamminger, Huang (bib0040) 2002; 80 Tan (bib0025) 2014; 6 Anonymous (bib0110) 2015 Shapira, Resnick, Chou, Neumann, Lurain, Stamminger, Caplan, Saleh, Efferth, Marschall, Wolf (bib0075) 2008; 46 Tanaka, Kimura, Iida, Saito, Tsuge, Yoshimi, Matsuyama, Morishima (bib0090) 2000; 60 Hakki, Chou (bib0030) 2011; 24 Kimberlin, Aban, Acosta (bib0100) 2015; 372 Mott, He, Chen, Fox, Civin, Arav-Boger, Posner (bib0065) 2013; 21 Mareri, Lasorella, Iapadre, Maresca, Tambucci, Nigro (bib0020) 2015 Arav-Boger, He, Chiou, Liu, Woodard, Rosenthal, Jones-Brando, Forman, Posner (bib0050) 2010; 5 He, Sandford, Hayward, Burns, Posner, Forman, Arav-Boger (bib0055) 2011; 8 Kimberlin, Jester, Sanchez, Ahmed, Arav-Boger, Michaels, Ashouri, Englund, Estrada, Jacobs, Romero, Sood, Whitworth, Abzug, Caserta, Fowler, Lujan-Zilbermann, Storch, DeBiasi, Han, Palmer, Weiner, Bocchini, Dennehy, Finn, Griffiths, Luck, Gutierrez, Halasa, Homans, Shane, Sharland, Simonsen, Vanchiere, Woods, Sabo, Aban, Kuo, James, Prichard, Griffin, Giles, Acosta, Whitley, National Institute of A Infectious Diseases Collaborative Antiviral Study Group (bib0105) 2015; 372 Ribeiro, Olliaro (bib0070) 1998; 58 26083215 - N Engl J Med. 2015 Jun 18;372(25):2463 25738669 - N Engl J Med. 2015 Mar 5;372(10):933-43 20442781 - PLoS One. 2010;5(4):e10370 21269468 - Virol J. 2011;8:40 11976732 - J Mol Med (Berl). 2002 Apr;80(4):233-42 23673218 - Bioorg Med Chem. 2013 Jul 1;21(13):3702-7 26391432 - Aust N Z J Obstet Gynaecol. 2016 Feb;56(1):9-18 10686030 - J Med Virol. 2000 Apr;60(4):455-62 20388893 - JAMA. 2010 Apr 14;303(14):1375-82 24184983 - Antiviral Res. 2014 Jan;101:57-61 14723987 - Lancet. 2004 Jan 3;363(9402):9-17 20667769 - J Clin Virol. 2010 Sep;49(1):32-6 18699744 - Clin Infect Dis. 2008 Sep 15;47(6):804-11 26135794 - J Matern Fetal Neonatal Med. 2016;29(10):1657-64 25999800 - Curr Treat Options Infect Dis. 2014;6(3):256-270 18419454 - Clin Infect Dis. 2008 May 1;46(9):1455-7 23827788 - J Clin Virol. 2013 Sep;58(1):276-8 22001948 - Curr Opin Infect Dis. 2011 Dec;24(6):605-11 23308079 - Future Virol. 2012 Mar 1;7(3):279-293 10212898 - Med Trop (Mars). 1998;58(3 Suppl):50-3 23774439 - Antimicrob Agents Chemother. 2013 Sep;57(9):4208-14 10432281 - J Exp Med. 1999 Jul 19;190(2):177-82 22547612 - Antimicrob Agents Chemother. 2012 Jul;56(7):3508-15 26451404 - Clin Microbiol Infect. 2014 Sep;20 Suppl 7:19-26 11159510 - Blood. 2001 Feb 15;97(4):867-74 25316174 - Rev Med Virol. 2014 Nov;24(6):420-33 Germi (10.1016/j.jcv.2016.02.006_bib0080) 2014; 101 Anonymous (10.1016/j.jcv.2016.02.006_bib0110) 2015 Buyck (10.1016/j.jcv.2016.02.006_bib0115) 2010; 49 He (10.1016/j.jcv.2016.02.006_bib0060) 2012; 56 Kimberlin (10.1016/j.jcv.2016.02.006_bib0100) 2015; 372 Hakki (10.1016/j.jcv.2016.02.006_bib0030) 2011; 24 Tanaka (10.1016/j.jcv.2016.02.006_bib0090) 2000; 60 Nichols (10.1016/j.jcv.2016.02.006_bib0120) 2001; 97 Tan (10.1016/j.jcv.2016.02.006_bib0025) 2014; 6 He (10.1016/j.jcv.2016.02.006_bib0095) 2013; 57 Adjuik (10.1016/j.jcv.2016.02.006_bib0035) 2004; 363 Shapira (10.1016/j.jcv.2016.02.006_bib0075) 2008; 46 Kimberlin (10.1016/j.jcv.2016.02.006_bib0105) 2015; 372 Gantt (10.1016/j.jcv.2016.02.006_bib0085) 2013; 58 La Rosa (10.1016/j.jcv.2016.02.006_bib0125) 2012; 7 Efferth (10.1016/j.jcv.2016.02.006_bib0045) 2008; 47 Naing (10.1016/j.jcv.2016.02.006_bib0015) 2015 Mott (10.1016/j.jcv.2016.02.006_bib0065) 2013; 21 Boppana (10.1016/j.jcv.2016.02.006_bib0130) 2010; 303 He (10.1016/j.jcv.2016.02.006_bib0055) 2011; 8 Efferth (10.1016/j.jcv.2016.02.006_bib0040) 2002; 80 Hamilton (10.1016/j.jcv.2016.02.006_bib0010) 2014; 24 Lumbreras (10.1016/j.jcv.2016.02.006_bib0005) 2014; 20 Arav-Boger (10.1016/j.jcv.2016.02.006_bib0050) 2010; 5 Emery (10.1016/j.jcv.2016.02.006_bib0135) 1999; 190 Ribeiro (10.1016/j.jcv.2016.02.006_bib0070) 1998; 58 Mareri (10.1016/j.jcv.2016.02.006_bib0020) 2015 |
References_xml | – volume: 190 start-page: 177 year: 1999 end-page: 182 ident: bib0135 article-title: The dynamics of human cytomegalovirus replication in vivo publication-title: J. Exp. Med. contributor: fullname: Griffiths – volume: 47 start-page: 804 year: 2008 end-page: 811 ident: bib0045 article-title: The antiviral activities of artemisinin and artesunate publication-title: Clin. Infect. Dis. contributor: fullname: Marschall – volume: 46 start-page: 1455 year: 2008 end-page: 1457 ident: bib0075 article-title: Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation publication-title: Clin. Infect. Dis. contributor: fullname: Wolf – volume: 57 start-page: 4208 year: 2013 end-page: 4214 ident: bib0095 article-title: Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety publication-title: Antimicrob. Agents Chemother. contributor: fullname: Arav-Boger – start-page: 07936 year: 2015 ident: bib0110 article-title: Coartem [Drug Insert] contributor: fullname: Anonymous – volume: 372 start-page: 2463 year: 2015 ident: bib0100 article-title: Valganciclovir for congenital cytomegalovirus publication-title: N. Engl. J. Med. contributor: fullname: Acosta – volume: 303 start-page: 1375 year: 2010 end-page: 1382 ident: bib0130 article-title: Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection publication-title: JAMA contributor: fullname: National Institute on Deafness and Other Communication Disorders CMV and Hearing Multicenter Screening Study – volume: 372 start-page: 933 year: 2015 end-page: 943 ident: bib0105 article-title: Valganciclovir for symptomatic congenital cytomegalovirus disease publication-title: N. Engl. J. Med. contributor: fullname: National Institute of A Infectious Diseases Collaborative Antiviral Study Group – volume: 6 start-page: 256 year: 2014 end-page: 270 ident: bib0025 article-title: Cytomegalovirus treatment publication-title: Curr. Treat. Options Infect. Dis. contributor: fullname: Tan – volume: 60 start-page: 455 year: 2000 end-page: 462 ident: bib0090 article-title: Quantitative analysis of cytomegalovirus load using a real-time PCR assay publication-title: J. Med. Virol. contributor: fullname: Morishima – volume: 8 start-page: 40 year: 2011 ident: bib0055 article-title: Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors publication-title: Virol. J. contributor: fullname: Arav-Boger – volume: 49 start-page: 32 year: 2010 end-page: 36 ident: bib0115 article-title: Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy publication-title: J. Clin. Virol. contributor: fullname: Emery – volume: 24 start-page: 605 year: 2011 end-page: 611 ident: bib0030 article-title: The biology of cytomegalovirus drug resistance publication-title: Curr. Opin. Infect. Dis. contributor: fullname: Chou – volume: 363 start-page: 9 year: 2004 end-page: 17 ident: bib0035 article-title: Artesunate combinations for treatment of malaria: meta-analysis publication-title: Lancet contributor: fullname: International Artemisinin Study – volume: 5 start-page: e10370 year: 2010 ident: bib0050 article-title: Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers publication-title: PLoS One contributor: fullname: Posner – volume: 20 start-page: 19 year: 2014 end-page: 26 ident: bib0005 article-title: Cytomegalovirus infection in solid organ transplant recipients publication-title: Clin. Microbiol. Infect. contributor: fullname: Hirsch – volume: 58 start-page: 276 year: 2013 end-page: 278 ident: bib0085 article-title: An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia publication-title: J. Clin. Virol. contributor: fullname: Casper – year: 2015 ident: bib0015 article-title: Congenital cytomegalovirus infection in pregnancy: a review of prevalence, clinical features, diagnosis and prevention publication-title: Aust. N. Z. J. Obstet. Gynaecol. contributor: fullname: Rawlinson – volume: 7 start-page: 279 year: 2012 end-page: 293 ident: bib0125 article-title: The immune response to human CMV publication-title: Future Virol. contributor: fullname: Diamond – volume: 97 start-page: 867 year: 2001 end-page: 874 ident: bib0120 article-title: Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes publication-title: Blood contributor: fullname: Boeckh – volume: 21 start-page: 3702 year: 2013 end-page: 3707 ident: bib0065 article-title: Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study publication-title: Bioorg. Med. Chem. contributor: fullname: Posner – volume: 80 start-page: 233 year: 2002 end-page: 242 ident: bib0040 article-title: Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses publication-title: J. Mol. Med. (Berl.) contributor: fullname: Huang – volume: 56 start-page: 3508 year: 2012 end-page: 3515 ident: bib0060 article-title: Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication publication-title: Antimicrob. Agents Chemother. contributor: fullname: Arav-Boger – volume: 58 start-page: 50 year: 1998 end-page: 53 ident: bib0070 article-title: Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials publication-title: Med. Trop. (Mars) contributor: fullname: Olliaro – year: 2015 ident: bib0020 article-title: Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects publication-title: J. Matern. Fetal Neonatal Med. contributor: fullname: Nigro – volume: 24 start-page: 420 year: 2014 end-page: 433 ident: bib0010 article-title: Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review publication-title: Rev. Med. Virol. contributor: fullname: Rawlinson – volume: 101 start-page: 57 year: 2014 end-page: 61 ident: bib0080 article-title: Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus publication-title: Antiviral Res. contributor: fullname: Morand – volume: 57 start-page: 4208 year: 2013 ident: 10.1016/j.jcv.2016.02.006_bib0095 article-title: Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00893-13 contributor: fullname: He – volume: 24 start-page: 605 year: 2011 ident: 10.1016/j.jcv.2016.02.006_bib0030 article-title: The biology of cytomegalovirus drug resistance publication-title: Curr. Opin. Infect. Dis. doi: 10.1097/QCO.0b013e32834cfb58 contributor: fullname: Hakki – start-page: 07936 year: 2015 ident: 10.1016/j.jcv.2016.02.006_bib0110 contributor: fullname: Anonymous – volume: 303 start-page: 1375 year: 2010 ident: 10.1016/j.jcv.2016.02.006_bib0130 article-title: Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection publication-title: JAMA doi: 10.1001/jama.2010.423 contributor: fullname: Boppana – year: 2015 ident: 10.1016/j.jcv.2016.02.006_bib0020 article-title: Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects publication-title: J. Matern. Fetal Neonatal Med. contributor: fullname: Mareri – volume: 47 start-page: 804 year: 2008 ident: 10.1016/j.jcv.2016.02.006_bib0045 article-title: The antiviral activities of artemisinin and artesunate publication-title: Clin. Infect. Dis. doi: 10.1086/591195 contributor: fullname: Efferth – volume: 372 start-page: 933 year: 2015 ident: 10.1016/j.jcv.2016.02.006_bib0105 article-title: Valganciclovir for symptomatic congenital cytomegalovirus disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1404599 contributor: fullname: Kimberlin – volume: 363 start-page: 9 year: 2004 ident: 10.1016/j.jcv.2016.02.006_bib0035 article-title: Artesunate combinations for treatment of malaria: meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(03)15162-8 contributor: fullname: Adjuik – volume: 97 start-page: 867 year: 2001 ident: 10.1016/j.jcv.2016.02.006_bib0120 article-title: Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes publication-title: Blood doi: 10.1182/blood.V97.4.867 contributor: fullname: Nichols – volume: 5 start-page: e10370 year: 2010 ident: 10.1016/j.jcv.2016.02.006_bib0050 article-title: Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers publication-title: PLoS One doi: 10.1371/journal.pone.0010370 contributor: fullname: Arav-Boger – volume: 190 start-page: 177 year: 1999 ident: 10.1016/j.jcv.2016.02.006_bib0135 article-title: The dynamics of human cytomegalovirus replication in vivo publication-title: J. Exp. Med. doi: 10.1084/jem.190.2.177 contributor: fullname: Emery – volume: 101 start-page: 57 year: 2014 ident: 10.1016/j.jcv.2016.02.006_bib0080 article-title: Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2013.10.014 contributor: fullname: Germi – volume: 46 start-page: 1455 year: 2008 ident: 10.1016/j.jcv.2016.02.006_bib0075 article-title: Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation publication-title: Clin. Infect. Dis. doi: 10.1086/587106 contributor: fullname: Shapira – volume: 56 start-page: 3508 year: 2012 ident: 10.1016/j.jcv.2016.02.006_bib0060 article-title: Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00519-12 contributor: fullname: He – volume: 6 start-page: 256 year: 2014 ident: 10.1016/j.jcv.2016.02.006_bib0025 article-title: Cytomegalovirus treatment publication-title: Curr. Treat. Options Infect. Dis. doi: 10.1007/s40506-014-0021-5 contributor: fullname: Tan – volume: 24 start-page: 420 year: 2014 ident: 10.1016/j.jcv.2016.02.006_bib0010 article-title: Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review publication-title: Rev. Med. Virol. doi: 10.1002/rmv.1814 contributor: fullname: Hamilton – volume: 60 start-page: 455 year: 2000 ident: 10.1016/j.jcv.2016.02.006_bib0090 article-title: Quantitative analysis of cytomegalovirus load using a real-time PCR assay publication-title: J. Med. Virol. doi: 10.1002/(SICI)1096-9071(200004)60:4<455::AID-JMV14>3.0.CO;2-Q contributor: fullname: Tanaka – volume: 372 start-page: 2463 year: 2015 ident: 10.1016/j.jcv.2016.02.006_bib0100 article-title: Valganciclovir for congenital cytomegalovirus publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1404599 contributor: fullname: Kimberlin – volume: 20 start-page: 19 issue: Suppl. 7 year: 2014 ident: 10.1016/j.jcv.2016.02.006_bib0005 article-title: Cytomegalovirus infection in solid organ transplant recipients publication-title: Clin. Microbiol. Infect. doi: 10.1111/1469-0691.12594 contributor: fullname: Lumbreras – volume: 8 start-page: 40 year: 2011 ident: 10.1016/j.jcv.2016.02.006_bib0055 article-title: Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors publication-title: Virol. J. doi: 10.1186/1743-422X-8-40 contributor: fullname: He – volume: 58 start-page: 276 year: 2013 ident: 10.1016/j.jcv.2016.02.006_bib0085 article-title: An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2013.06.008 contributor: fullname: Gantt – volume: 49 start-page: 32 year: 2010 ident: 10.1016/j.jcv.2016.02.006_bib0115 article-title: Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2010.06.018 contributor: fullname: Buyck – volume: 7 start-page: 279 year: 2012 ident: 10.1016/j.jcv.2016.02.006_bib0125 article-title: The immune response to human CMV publication-title: Future Virol. doi: 10.2217/fvl.12.8 contributor: fullname: La Rosa – volume: 80 start-page: 233 year: 2002 ident: 10.1016/j.jcv.2016.02.006_bib0040 article-title: Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses publication-title: J. Mol. Med. (Berl.) doi: 10.1007/s00109-001-0300-8 contributor: fullname: Efferth – year: 2015 ident: 10.1016/j.jcv.2016.02.006_bib0015 article-title: Congenital cytomegalovirus infection in pregnancy: a review of prevalence, clinical features, diagnosis and prevention publication-title: Aust. N. Z. J. Obstet. Gynaecol. contributor: fullname: Naing – volume: 21 start-page: 3702 year: 2013 ident: 10.1016/j.jcv.2016.02.006_bib0065 article-title: Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2013.04.027 contributor: fullname: Mott – volume: 58 start-page: 50 year: 1998 ident: 10.1016/j.jcv.2016.02.006_bib0070 article-title: Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials publication-title: Med. Trop. (Mars) contributor: fullname: Ribeiro |
SSID | ssj0015347 |
Score | 2.2732074 |
Snippet | Highlights • CMV shedding is common in Mali, a malaria-endemic area. • Most children have low level of CMV shedding in the urine. • Artemisinin-based therapy... •CMV shedding is common in Mali, a malaria-endemic area.•Most children have low level of CMV shedding in the urine.•Artemisinin-based therapy for malaria may... Artemisinins, commonly used to treat malaria, have shown activity against cytomegalovirus (CMV) in vitro, in an animal model, and in case reports; however, the... BACKGROUNDArtemisinins, commonly used to treat malaria, have shown activity against cytomegalovirus (CMV) in vitro, in an animal model, and in case reports;... Background Artemisinins, commonly used to treat malaria, have shown activity against cytomegalovirus (CMV) in vitro, in an animal model, and in case reports;... |
SourceID | pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 40 |
SubjectTerms | Allergy and Immunology Artemether-lumefantrine Artemisinins - therapeutic use Child Child, Preschool Coinfection Cytomegalovirus Cytomegalovirus Infections - diagnosis Cytomegalovirus Infections - virology Drug Combinations Ethanolamines - therapeutic use Female Fluorenes - therapeutic use Follow-Up Studies Humans Infant Infectious Disease Malaria Malaria - diagnosis Malaria - drug therapy Malaria - parasitology Male Parasite Load Treatment Outcome Urine viral load Viral Load Virus Shedding |
Title | Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1386653216000676 https://dx.doi.org/10.1016/j.jcv.2016.02.006 https://www.ncbi.nlm.nih.gov/pubmed/26895228 https://search.proquest.com/docview/1773428497 https://search.proquest.com/docview/1785244086 https://pubmed.ncbi.nlm.nih.gov/PMC4792724 |
Volume | 77 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLaqIiQuiJ1hqYzEAZDMTLzEybEaUQ0geoFKvVlObItUnaSapagXjvxu3rOTiKGiB45JXhb7rVa-95mQ176qhAcnY1AqKya148xmlWNZsNJJ7YOO3J1fjvPFifx0qk73yHzohUFYZR_7U0yP0bo_M-1nc3rRNNOvmUCuNsGzPMZcpN2WkP7Apt__HGEe4NBxkzEUZig9_NmMGK-z-hLRXXmi7cz_lZuu155_Qyj_yElH98jdvpikh-l775M93z4gt9P2klcPya9ETUy7QBG5uYy9vQyjUYD5xLY_-mbexUtvadfS-mrTLT2kjO6yWW3XdBtFEAV8Ts8762jqaaS2dTSA_XQ_8GiEqsO5FV1aWCo3ljbwuL5P_BE5Ofrwbb5g_b4LrFai3LAi1LAME9ZxX_IKO3FVKApw7QIUG1zusGxRttalnQXhVe6kUlBXIXsYhAMnHpP9tmv9U0JnflbUmXSZ9U5mtS2w3rJISqiDCLyakHfDjJuLRK9hBtzZmQH1GFSPmXED6pkQPejEDH2jEOn8une7tcnMGiTNNdOYEDneuWNdBhLHTS98NWjegNfhrxTb-m4LL9JawMJNlvommUJx3NAbnvMkWcs4Rp4XJVS-BQxpx45GAWT93r3SNt8j-7fUJddcPvu_IT0nd_AoYY9ekP3NautfQlm1qQ6i3xyQW4cfPy-OfwMb-CQW |
link.rule.ids | 230,315,783,787,888,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLZKEYILYmfKZiQOgJTOxHZi54hGVAO0vdBKvVlObItUnbiapVUvHPndvOcsYqjogWPil8V-i5_l730m5J0rS-7AyRJIlbNESMsSk5Y2Sb0RVkjnZeTuPDjMZ8fi60l2skWmfS0Mwiq72N_G9BituzvjbjTH53U9_p5y5GrjLM1jzM1vkdsC82Mw6t2fA84DPDqeMobSCYr3W5sR5HVaXSC8K295O_N_TU7Xk8-_MZR_TEp7D8j9Lpukn9offki2XPOI3GnPl7x6TH613MQ0eIrQzXks7k0wHHkYUKz7o--nITZ9oKGh1dUqzB3MGeGiXqyXdB1FEAZ8Rs-CsbQtaqSmsdSDAYVLvBqw6nBvQecG1sq1oTW8risUf0KO9z4fTWdJd_BCUmW8WCXKV7AO48YyV7ASS3EzrxT4tgLNeptbzFsyU8nCTDx3WW5h4CGxQvowiAeWPyXbTWjcc0InbqKqVNjUOCvSyihMuAyyEkrPPStH5GM_4vq85dfQPfDsVIN6NKpHT5gG9YyI7HWi-8JRCHVu2fndUqd6CZL6mm2MiBie3DAvDTPHTR9822teg9vhXoppXFjDh6TksHIThbxJRmUMT_SG9zxrrWXoI8tVAamvgi5t2NEggLTfmy1N_SPSfwtZMMnEzv916Q25Ozs62Nf7Xw6_vSD3sKUFIr0k26vF2r2CHGtVvo4-9Buu5CWv |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+artemether-lumefantrine+%28Coartem%29+on+cytomegalovirus+urine+viral+load+during+and+following+treatment+for+malaria+in+children&rft.jtitle=Journal+of+clinical+virology&rft.au=Barger-Kamate%2C+Breanna&rft.au=Forman%2C+Michael&rft.au=Sangare%2C+Cheik+Oumar&rft.au=Haidara%2C+Aboubecrin+Sedhigh+A&rft.date=2016-04-01&rft.eissn=1873-5967&rft.volume=77&rft.spage=40&rft_id=info:doi/10.1016%2Fj.jcv.2016.02.006&rft_id=info%3Apmid%2F26895228&rft.externalDocID=26895228 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1386-6532&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1386-6532&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1386-6532&client=summon |